A Phase 1 interventional study of Tirzepatide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 47th largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1, and was the 3rd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 92nd largest by enrollment of the 117 interventional ones that give a count, is one of 3 that started in 2020, is one of 40 in phase 1, and was the 4th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tirzepatide 5 milligrams (mg) once a week (QW) for Weeks 1 through 3 followed by tirzepatide 10 mg QW for Weeks 4 through 6 into the subcutaneous (SC) tissue of the abdominal wall.
Drug: Tirzepatide
Participants received placebo administered into the SC tissue of the abdominal wall.
Drug: Placebo
Participants received Liraglutide with step wise dose escalation regimen starting from 0.6 mg once daily (QD) for week 1 followed by 1.2 mg QD for week 2, 1.8 mg QD for week 3, 2.4 mg QD for Week 4 followed by 3 mg QD starting in Week 5 and maintained for 10 days administered into the SC tissue of the abdominal wall.
Drug: Liraglutide
Administered SC.
Also known as: LY3298176
Administered SC.
Administered SC.
Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3
Change from baseline in calorie intake in participants receiving tirzepatide or placebo at week 3 is reported.
Time frame: Baseline, Week 3
Change From Baseline in Blood Oxygen Level-dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Response to Images of Highly Palatable Food Relative to Nonfood Item During Fasting State in the 5 Brain Reward Areas
Change from baseline in BOLD fMRI signals in response to images of highly palatable foods (high fat-high sugar and high fat-high carbohydrate) relative to nonfood items during the fasting state in the brain reward areas (Insula, medial frontal gyrus, superior temporal gyrus, precentral gyrus, and cingulate gyrus) at Week 3 is reported. fMRI is a functional neuroimaging procedure that uses MRI technology to measure brain activity by detecting associated changes in blood flow. When an area of the brain is in use, blood flow to that region increases. The activation in response to the processing of viewing food images in each brain reward areas was measured by the signal change in BOLD response. Least squares (LS) mean was calculated using mixed-model repeated measures (MMRM) model with covariates Baseline + Treatment + Baseline Body mass index (BMI) Stratum + Scanner Identification + Week + Treatment\*Week + Participant + Random Error.
Time frame: Baseline, Week 3
Change From Baseline in Fasting and Postprandial Overall Appetite Visual Analog Scale (VAS) Score
The VAS determines the effects on appetite sensations and desire for specific foods. It consists of 8 individual questions that measure hunger, satiety, fullness, prospective food consumption, desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food. The VAS scales will be analyzed as continuous variables on the 0-100 scale for 8 individual components. Hunger, satiety, fullness, prospective food consumption are rated as 0=Not at all and 100=Extremely. Desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food are rated as 0=Yes, very much and 100=No, not at all. Overall appetite score is calculated as the average of the first 4 individual scores (satiety + fullness + \[100-prospective food consumption\] + \[100-hunger\]/4). The higher overall appetite score indicates less appetite, and the lower score indicates more appetite.
Time frame: Baseline, Week 3
| Milestone | Placebo | Tirzepatide | Liraglutide |
|---|---|---|---|
| Started | 39 | 37 | 38 |
| Received at least one dose of study drug | 39 | 37 | 38 |
| Completed | 34 | 31 | 36 |
| Not completed | 5 | 6 | 2 |
| Withdrew: Adverse event | 2 | 3 | 2 |
| Withdrew: Withdrawal by subject | 3 | 3 | 0 |
Change from baseline in calorie intake in participants receiving tirzepatide or placebo at week 3 is reported.
| kilocalories (kcal) | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3 | 10.95 ± 49.06 | -523.15 ± 52.78 |
Change from baseline in BOLD fMRI signals in response to images of highly palatable foods (high fat-high sugar and high fat-high carbohydrate) relative to nonfood items during the fasting state in the brain reward areas (Insula, medial frontal gyrus, superior temporal gyrus, precentral gyrus, and cingulate gyrus) at Week 3 is reported. fMRI is a functional neuroimaging procedure that uses MRI technology to measure brain activity by detecting associated changes in blood flow. When an area of the brain is in use, blood flow to that region increases. The activation in response to the processing of viewing food images in each brain reward areas was measured by the signal change in BOLD response. Least squares (LS) mean was calculated using mixed-model repeated measures (MMRM) model with covariates Baseline + Treatment + Baseline Body mass index (BMI) Stratum + Scanner Identification + Week + Treatment\*Week + Participant + Random Error.
| Arbitrary Units | Placebo | Tirzepatide | Liraglutide |
|---|---|---|---|
| Insula | -0.0739 ± 0.0740 | -0.0301 ± 0.0771 | 0.0190 ± 0.0738 |
| Medial frontal gyrus | 0.0504 ± 0.0649 | 0.0494 ± 0.0680 | 0.0581 ± 0.0658 |
| Superior temporal gyrus | 0.0132 ± 0.0838 | 0.0174 ± 0.0881 | 0.0621 ± 0.0839 |
| Precentral gyrus | 0.0441 ± 0.0580 | 0.0249 ± 0.0616 | 0.0845 ± 0.0593 |
| Cingulate gyrus | 0.0283 ± 0.0615 | 0.0214 ± 0.0643 | 0.0967 ± 0.0623 |
The VAS determines the effects on appetite sensations and desire for specific foods. It consists of 8 individual questions that measure hunger, satiety, fullness, prospective food consumption, desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food. The VAS scales will be analyzed as continuous variables on the 0-100 scale for 8 individual components. Hunger, satiety, fullness, prospective food consumption are rated as 0=Not at all and 100=Extremely. Desire for sweet food, desire for salty food, desire for savory food, and desire for fatty food are rated as 0=Yes, very much and 100=No, not at all. Overall appetite score is calculated as the average of the first 4 individual scores (satiety + fullness + \[100-prospective food consumption\] + \[100-hunger\]/4). The higher overall appetite score indicates less appetite, and the lower score indicates more appetite.
| score on a scale | Placebo | Tirzepatide | Liraglutide |
|---|---|---|---|
| Fasting (Pre-lunch) | 2.15 ± 3.02 | 22.72 ± 3.30 | 8.78 ± 3.11 |
| Postprandial (Post-lunch) | -0.59 ± 2.08 | 1.66 ± 2.23 | 0.05 ± 2.12 |
Collected over Baseline up to 10 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/39 (0%) | 0/39 (0%) | 11/39 (28.2%) |
| Tirzepatide | 0/37 (0%) | 0/37 (0%) | 29/37 (78.4%) |
| Liraglutide | 0/38 (0%) | 1/38 (2.6%) | 20/38 (52.6%) |
| Event | Placebo | Tirzepatide | Liraglutide |
|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/39 | 0/37 | 1/38 |
| Event | Placebo | Tirzepatide | Liraglutide |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/39 | 19/37 | 11/38 |
| VomitingGastrointestinal disorders | 1/39 | 11/37 | 4/38 |
| ConstipationGastrointestinal disorders | 0/39 | 7/37 | 5/38 |
| DyspepsiaGastrointestinal disorders | 1/39 | 7/37 | 2/38 |
| HeadacheNervous system disorders | 3/39 | 7/37 | 3/38 |
| Abdominal distensionGastrointestinal disorders | 0/39 | 5/37 | 1/38 |
| DiarrhoeaGastrointestinal disorders | 2/39 | 5/37 | 1/38 |
| Abdominal pain upperGastrointestinal disorders | 1/39 | 4/37 | 1/38 |
| FlatulenceGastrointestinal disorders | 2/39 | 4/37 | 2/38 |
| Injection site reactionGeneral disorders | 1/39 | 4/37 | 1/38 |
All participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Tirzepatide | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 46.2 ± 9.5 | 44.8 ± 10.2 | 43.7 ± 11.9 | 44.9 ± 10.5 |
| Sex: Female, Male(Participants) | Placebo | Tirzepatide | Liraglutide | Total |
|---|---|---|---|---|
| Female | 36 | 36 | 25 | 97 |
| Male | 3 | 1 | 13 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tirzepatide | Liraglutide | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 3 | 5 |
| Not Hispanic or Latino | 37 | 36 | 35 | 108 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Tirzepatide | Liraglutide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 11 | 9 | 10 | 30 |
| White | 28 | 27 | 28 | 83 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Tirzepatide | Liraglutide | Total |
|---|---|---|---|---|
| United States | 39 | 37 | 38 | 114 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Dec 2022, 27 months.
Results were first posted in May 2024, 1 year 5 months after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 27 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide